Literature DB >> 2013514

Spontaneous release of interferon as a predictor of clinical evolution in HIV-positive subjects.

A Biglino1, A Surbone, F Lipani, N Cappello, B Forno, A M Pollono, M Busso, A Pugliese.   

Abstract

In order to establish a correlation with disease progression we prospectively evaluated ten clinical and immunologic parameters in 102 consecutive HIV-positive subjects. The eight immunologic variables were: in vitro spontaneous interferon release by peripheral blood monocytic cells, alpha- and gamma-interferon production induced by Newcastle Disease Virus and PHA, Multitest Mérieux score, PHA- and CON-A-induced lymphocyte transformation, absolute number of CD4+ cells and CD4/CD8 ratio, respectively. The two baseline clinical variables were risk factor and disease presentation. Generalized Wilcoxon analysis indicated a significant correlation of one clinical (disease presentation at entry) and three immunologic variables (spontaneous interferon release, CD4+ cell number, Multitest Mérieux) with disease progression. Baseline spontaneous release of alpha, acid-labile interferon showed the best correlation with disease progression, and appeared to be significantly associated with CD4+ cell loss. Spontaneous release of acid-labile alpha interferon by mononuclear cells in vitro could be highly predictive of disease evolution in HIV-Ab positive, AIDS-free subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013514     DOI: 10.1007/bf01643747

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  28 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Lymphocyte transformation response to pokeweed mitogen as a predictive marker for development of AIDS and AIDS related symptoms in homosexual men with HIV antibodies.

Authors:  B Hofmann; B O Lindhardt; J Gerstoft; C S Petersen; P Platz; L P Ryder; N Odum; E Dickmeiss; P B Nielsen; S Ullman
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

3.  Impaired T-lymphocyte-dependent immune responses to microbial antigens in patients with HIV-1-associated persistent generalized lymphadenopathy.

Authors:  J J Ballet; L J Couderc; C Rabian-Herzog; C Duval-Roy; M Janier; F Danon; J P Clauvel; M Seligmann
Journal:  AIDS       Date:  1988-08       Impact factor: 4.177

4.  Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases.

Authors: 
Journal:  MMWR Suppl       Date:  1987-08-14

5.  Interferon production in patients infected with HIV-1.

Authors:  S Rossol; R Voth; H P Laubenstein; W E Müller; H C Schröder; K H Meyer zum Büschenfelde; G Hess
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

6.  The multi-test system: a standardized approach to evaluation of delayed hypersensitivity and cell-mediated immunity.

Authors:  W T Kniker; C T Anderson; M Roumiantzeff
Journal:  Ann Allergy       Date:  1979-08

7.  AIDS as immune system activation: a model for pathogenesis.

Authors:  M S Ascher; H W Sheppard
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

8.  Intradermal testing with multiple recall antigens for identification of cell-mediated immune deficiency in homosexual men.

Authors:  G Bratt; G von Krogh; L Moberg; A Karlsson; P O Putkonen; G Biberfeld; M Böttiger; E Sandström
Journal:  Clin Immunol Immunopathol       Date:  1986-11

9.  T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome.

Authors:  H W Murray; D A Scavuzzo; C D Kelly; B Y Rubin; R B Roberts
Journal:  Arch Intern Med       Date:  1988-07

10.  Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1.

Authors:  P Roux-Lombard; C Modoux; A Cruchaud; J M Dayer
Journal:  Clin Immunol Immunopathol       Date:  1989-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.